Tumor-associated macrophages subvert t-cell function and correlate with reduced survival in clear cell renal cell carcinoma

OncoImmunology

Volumn 2, Issue 3, 2013, Pages

  Dannenmann, Stefanie Regine ^a   Thielicke, Julia ^a   Stöckli, Martina ^a   Matter, Claudia ^a   von Boehmer, Lotta ^a   Cecconi, Virginia ^a   Hermanns, Thomas ^a   Hefermehl, Lukas ^a   Schraml, Peter ^a   Moch, Holger ^a   Knuth, Alexander ^a   van den Broek, Maries ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Clear cell renal cell carcinoma; Immunoregulation; T cell response; Tumor immunology; Tumor associated macrophages

Indexed keywords

CD11B ANTIGEN; CD163 ANTIGEN; CD68 ANTIGEN; FIBRONECTIN; FIBRONECTIN 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; MEMBRANE PROTEIN; MESSENGER RNA; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN M2; T CELL IMMUNOGLOBULIN MUCIN 3; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BIOACCUMULATION; BONE MARROW CELL; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FIBRONECTIN 1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOREGULATION; INTERFERON REGULATORY FACTOR 4 GENE; KIDNEY CARCINOMA; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84886945385     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23562     Document Type: Article

References (52)

1. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science. 1203486.
3. Beck C, Schreiber H, Rowley D. Role of TGFbeta in immune-evasion of cancer. Microsc Res Tech 2001; 52:387-95; PMID:11170297; http://dx.doi.org/10.1002/1097-0029(20010215)52:4<387::AIDJEMT1023>3.0.CO;2-W.
4. Kawamura K, Bahar R, Natsume W, Sakiyama S, Tagawa M. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther 2002; 9:109-15; PMID:11916240; http://dx.doi.org/10.1038/sj.cgt.7700418.
5. Sica A, Schioppa T, Mantovani A, Allavena P. Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42:717-27; PMID:16520032; http://dx.doi.org/10.1016/j.ejca.2006.01.003.
6. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61:255-63; PMID:22120756; http://dx.doi.org/10.1007/s00262-011-1161-9.
7. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72:2162-71; PMID:22549946; http://dx.doi.org/10.1158/0008-5472.CAN-11-3687.
8. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66:605-12; PMID:16423985; http://dx.doi.org/10.1158/0008-5472.CAN-05-4005.
9. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression.Semin Cancer Biol 2008; 18:349-55; PMID:18467122; http://dx.doi.org/10.1016/j.semcancer.2008.03.004.
10. Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P, et al. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer.Clin Exp Metastasis 2007; 24:121-30; PMID:17390111; http://dx.doi.org/10.1007/s10585-007-9060-3.
11. Krausgruber T, Saliba D, Ryzhakov G, Lanfrancotti A, Blazek K, Udalova IA. IRF5 is required for latephase TNF secretion by human dendritic cells. Blood 2010; 115:4421-30; PMID:20237317; http://dx.doi.org/10.1182/blood-2010-01-263020.
12. Keller R, Geiges M, Keist R. L-arginine-dependent reactive nitrogen intermediates as mediators of tumor cell killing by activated macrophages. Cancer Res 1990; 50:1421-5; PMID:2302707.
13. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection.Nat Immunol 2010; 11:936-44; PMID:20729857; http://dx.doi.org/10.1038/ni.1920.
14. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples.Am J Clin Pathol 2004; 122:794-801; PMID:15491976; http://dx.doi.org/10.1309/QHD6YFN81KQXUUH6.
15. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation.J Exp Med 1992; 176:287-92; PMID:1613462; http://dx.doi.org/10.1084/jem.176.1.287.
16. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyteto-macrophage differentiation and polarization: new molecules and patterns of gene expression.J Immunol 2006; 177:7303-11; PMID:17082649.
17. Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.J Clin Oncol 2010; 28:311-7; PMID:19933918; http://dx.doi.org/10.1200/JCO.2009.22.4816.
18. Vickers MM, Heng DY. Prognostic and predictive biomarkers in renal cell carcinoma.Target Oncol 2010; 5:85-94; PMID:20582732; http://dx.doi.org/10.1007/s11523-010-0143-8.
19. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma.N Engl J Med 1996; 335:865-75; PMID:8778606; http://dx.doi.org/10.1056/NEJM199609193351207.
20. Gouttefangeas C, Stenzl A, Stevanovic S, Rammensee HG. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 2007; 56:117-28; PMID:16676181; http://dx.doi.org/10.1007/s00262-006-0172-4.
21. Morra L, Rechsteiner M, Casagrande S, Duc Luu V, Santimaria R, Diener PA, et al.Relevance of periostin splice variants in renal cell carcinoma.Am J Pathol 2011; 179:1513-21; PMID:21763681; http://dx.doi.org/10.1016/j.ajpath.2011.05.035.
22. Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, Amabile A, et al. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 2012; 119:411-21; PMID:22067385; http://dx.doi.org/10.1182/blood-2011-02-339911.
23. Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, van Lin EN, Osanto S, de Mulder PH. Guideline 'Renal cell carcinoma'.Ned Tijdschr Geneeskd 2008; 152:376-80; PMID:18380384.
24. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis.Cell 2010; 141:39-51; PMID:20371344; http://dx.doi.org/10.1016/j.cell.2010.03.014.
25. Patsialou A, Wyckoff J, Wang Y, Goswami S, Stanley ER, Condeelis JS. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res 2009; 69:9498-506; PMID:19934330; http://dx.doi.org/10.1158/0008-5472.CAN-09-1868.
26. Gertler F, Condeelis J. Metastasis: tumor cells becoming MENAcing.Trends Cell Biol 2011; 21:81-90; PMID:21071226; http://dx.doi.org/10.1016/j.tcb.2010.10.001.
27. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance.Annu Rev Immunol 2004; 22:745-63; PMID:15032595; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104702.
28. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al.Molecular signature of CD8+ T cell exhaustion during chronic viral infection.Immunity 2007; 27:670-84; PMID:17950003; http://dx.doi.org/10.1016/j.immuni.2007.09.006.
29. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, et al.Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009; 69:8412-9; PMID:19843860; http://dx.doi.org/10.1158/0008-5472.CAN-09-0852.
30. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al.Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.J Exp Med 2009; 206:1327-37; PMID:19451266; http://dx.doi.org/10.1084/jem.20082173.
31. Savage ND, de Boer T, Walburg KV, Joosten SA, van Meijgaarden K, Geluk A, et al.Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membranebound TGFbeta-1.J Immunol 2008; 181:2220-6; PMID:18641362.
32. Vasievich EA, Huang L. The suppressive tumor microenvironment: a challenge in cancer immunotherapy.Mol Pharm 2011; 8:635-41; PMID:21545153; http://dx.doi.org/10.1021/mp1004228.
33. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, et al.Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61:5132-6; PMID:11431351.
34. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, Futatsuyama K, et al.Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006; 97:780-6; PMID:16863511; http://dx.doi.org/10.1111/j.1349-7006.2006.00231.x.
35. Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery.J Clin Invest 2003; 112:1310-2; PMID:14597756.
36. Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, et al.Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007; 56:1743-53; PMID:17487490; http://dx.doi.org/10.1007/s00262-007-0318-z.
37. Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, et al.A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients.J Immunother 2010; 33:991-8; PMID:20948437; http://dx.doi.org/10.1097/CJI.0b013e3181f4c208.
38. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells.Adv Immunol 2003; 81:331-71; PMID:14711059; http://dx.doi.org/10.1016/S0065-2776(03)81008-8.
39. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, et al.Tumorinfiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.Clin Cancer Res 2007; 13:2075-81; PMID:17404089; http://dx.doi.org/10.1158/1078-0432.CCR-06-2139.
40. Li JF, Chu YW, Wang GM, Zhu TY, Rong RM, Hou J, et al. The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma.BJU Int 2009; 103:399-405; PMID:19021626; http://dx.doi.org/10.1111/j.1464-410X.2008.08151.x.
41. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993; 81:1607-13; PMID:7680921.
42. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm.J Immunol 2000; 164:6166-73; PMID:10843666.
43. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471-4906(02)02302-5.
44. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions.Immunity 2010; 32:593-604; PMID:20510870; http://dx.doi.org/10.1016/j.immuni.2010.05.007.
45. Ropponen KM, Kellokoski JK, Lipponen PK, Eskelinen MJ, Alanne L, Alhava EM, et al.Expression of inducible nitric oxide synthase in colorectal cancer and its association with prognosis.Scand J Gastroenterol 2000; 35:1204-11; PMID:11145294; http://dx.doi.org/10.1080/003655200750056709.
46. Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, et al.Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood 2010; 115:5053-6; PMID:20375314; http://dx.doi.org/10.1182/blood-2009-11-253260.
47. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.J Pathol 2008; 216:15-24; PMID:18553315; http://dx.doi.org/10.1002/path.2370.
48. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours.Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175.
49. Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 2011; 102:1424-31; PMID:21453387; http://dx.doi.org/10.1111/j.1349-7006.2011.01945.x.
50. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.Immunol Res 2011; 51:170-82; PMID:22139852; http://dx.doi.org/10.1007/s12026-011-8262-6.
51. Daurkin I, Eruslanov E, Stoffs T, Perrin GQ, Algood C, Gilbert SM, et al.Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res 2011; 71:6400-9; PMID:21900394; http://dx.doi.org/10.1158/0008-5472.CAN-11-1261.
52. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al.Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+ T cell dysfunction in melanoma patients.J Exp Med 2010; 207:2175-86; PMID:20819923; http://dx.doi.org/10.1084/jem.20100637